Puxitatug samrotecan
Puxitatug samrotecan (AZD8205) is an antibody-drug conjugate (ADC) targeting B7-H4. Puxitatug samrotecan is composed of the Puxitatug antibody targeting B7-H4, randomly conjugated to the Puxitatug samrotecan drug-linker (HY-163487) by reducing inter-chain cysteines. Puxitatug samrotecan has anti-tumor activity and can be used in the study of cancers expressing B7-H4[1].
Product Specifications
CAS Number
2760250-80-2
Product Name Alternative
AZD 8205
UNSPSC
12352203
Target
Antibody-Drug Conjugates (ADCs)
Related Pathways
Antibody-drug Conjugate/ADC Related
Applications
Cancer-programmed cell death
Field of Research
Cancer
Purity
98.01
Smiles
[Puxitatugsamrotecan]
References & Citations
[1]Kinneer K, et al. Design and Preclinical Evaluation of a Novel B7-H4-Directed Antibody-Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305. Clin Cancer Res. 2023 Mar 14;29 (6) :1086-1101.
Shipping Conditions
Dry Ice
Storage Conditions
-80°C, protect from light
Scientific Category
ADC Related
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
MR207312L3V 200 µL
Ttyh1 (NM_001001454) Mouse Tagged ORF Clone Lentiviral Particle
Sign In for Pricing
View Details 
